Ads
related to: alk lymphoma kinase symptoms treatment medications chart- Take The Quiz
Find Out If This Treatment Option
Could Be Right For You
- Real Patient Stories
Read About Patients Who Received
CAR T Cell Therapy Treatment
- Treatment Process
Learn The Steps Involved When
Receiving CAR T Cell Therapy
- Safety & Side Effects
Learn About Potential Side Effects
And Important Safety Information
- Cell Therapy 360®
Access Assistance Programs Designed
to Support You Throughout Treatment
- Treatment Results
Read Clinical Studies And Discover
Benefits And Risks Of This Therapy
- Take The Quiz
Search results
Results From The WOW.Com Content Network
ALK inhibitors are anti-cancer drugs that act on tumours with variations of anaplastic lymphoma kinase (ALK) such as an EML4-ALK translocation. [1] They fall under the category of tyrosine kinase inhibitors , which work by inhibiting proteins involved in the abnormal growth of tumour cells.
Chronic lymphocytic leukaemia, mantle cell lymphoma and non-Hodgkin's lymphoma. Myelosuppression, hypokalaemia and tachycardia. Busulfan: IV, PO: Alkylates DNA. Conditioning treatment before haematopoietic stem cell transplantation (high dose, IV), chronic myeloid leukaemia, myelofibrosis, polycythaemia vera and essential thrombocytosis
Treatment must be continued indefinitely at present. [77] [78] [79] Ceritinib was approved by the FDA in April 2014 for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. [80]
B-cell Hodgkin's lymphoma, non-Hodgkin lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia Camrelizumab [22] mab: humanized: PD-1: hepatocellular carcinoma: Canakinumab [43] Ilaris: mab: human: IL-1: Y: cryopyrin-associated periodic syndrome, Yao's Syndrome, Adult Onset Still's Disease: Cantuzumab mertansine [42] mab: humanized ...
Ceritinib is an anaplastic lymphoma kinase (ALK) inhibitor primarily used for the treatment of ALK positive metastatic NSCLC. [8] [9] Previously, it was only indicated for patients who had developed resistant to crizotinib, another ALK inhibitor, but has since had its usage expanded to serve as a primary option for metastatic NSCLC.
In August 2011, the US Food and Drug Administration (FDA) approved crizotinib to treat certain late-stage (locally advanced or metastatic) non-small cell lung cancers that express the abnormal anaplastic lymphoma kinase (ALK) gene. [4] Approval required a companion molecular test for the EML4-ALK fusion.
Ads
related to: alk lymphoma kinase symptoms treatment medications chartcareinfo.mayoclinic.org has been visited by 100K+ users in the past month